Sarcoidosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.

Overview

There is no universally accepted classification system for sarcoidosis according to our knowledge, but in some references sarcoidosis is classified regarding the organ system involved. The lung is involved in 90% of patients diagnosed with sarcoidosis, thus sarcoidosis is generally classified into pulmonary sarcoidosis and extra-pulmonary sarcoidosis.

Classification

Scadding proposed a scoring system regarding the chest radiograph for pulmonary sarcoidosis in 1961.

stage 1: Hilar adenopathy alone

stage 2: Hilar adenopathy plus lung infiltrates

stage 3: Lung infiltrates alone

stage 4: Fibrosis^[1]

Scadding‘s classification correlates with prognosis. Individuals with stage 1 disease, have a 80% chance of resolution of hilar adenopathy and those with stage 3 disease, have less than 30% chance of CXR resolution. The limitations of Scadding‘s scoring system include: 1. It does not characterize extra-pulmonary sarcoidosis 2. There is a significant variability in staging even among experienced radiologists^[2].

References

↑ Scadding JG: Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. British medical journal 1961, 2(5261):1165-1172.
↑ Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S et al: Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009, 136(2):526-53

Template:WH Template:WS

[1] Scadding JG: Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. British medical journal 1961, 2(5261):1165-1172.

[2] Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S et al: Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009, 136(2):526-53

[1]

[2]